McKesson saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an upgrade from 68 to 74.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best-performing stocks typically have an RS Rating north of 80 as they begin their biggest climbs. See if McKesson can continue to show renewed price strength and hit that benchmark.
McKesson is trying to complete a flat base with a 737.89 buy point. See if it can break out in volume at least 40% higher than normal.
Earnings growth dropped last quarter from 64% to 5%, but the top line rose from 19% to 23%.
McKesson earns the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
